Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 7.8% – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price shot up 7.8% during trading on Monday . The stock traded as high as $27.30 and last traded at $27.09. 142,627 shares changed hands during trading, a decline of 51% from the average session volume of 290,740 shares. The stock had previously closed at $25.12.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on DNTH. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Oppenheimer raised their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. TD Cowen assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Dianthus Therapeutics has a consensus rating of “Buy” and a consensus price target of $46.43.

Dianthus Therapeutics Trading Up 7.6 %

The stock has a market cap of $800.30 million, a P/E ratio of -10.82 and a beta of 1.74. The stock’s 50-day moving average is $24.72 and its 200-day moving average is $26.59.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. On average, equities analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC grew its holdings in Dianthus Therapeutics by 40.5% during the third quarter. Janus Henderson Group PLC now owns 949,334 shares of the company’s stock worth $25,936,000 after acquiring an additional 273,670 shares during the period. State Street Corp grew its stake in shares of Dianthus Therapeutics by 101.4% in the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after purchasing an additional 413,425 shares during the last quarter. Great Point Partners LLC grew its stake in shares of Dianthus Therapeutics by 21.3% in the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock worth $19,615,000 after purchasing an additional 132,929 shares during the last quarter. Braidwell LP raised its holdings in shares of Dianthus Therapeutics by 34.6% in the 3rd quarter. Braidwell LP now owns 493,687 shares of the company’s stock worth $13,517,000 after purchasing an additional 126,836 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in Dianthus Therapeutics by 151.3% during the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock worth $11,984,000 after buying an additional 263,500 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.